rheumatoid arthritis

3 Drugs Under FDA Review With Blockbuster Potential
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
AbbVie
Upadacitinib
rheumatoid arthritis
Novartis
brolucizumab
wet age-related macular degeneration
Celgene
ozanimod
relapsing multiple sclerosis
Flag link:
Pfizer announces results from XELJANZ XR ORAL Shift study
Pfizer announces results from XELJANZ XR ORAL Shift study
Pharmaceutical Business Review
Pfizer
Xeljanz
clinical trials
rheumatoid arthritis
Flag link:
Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose
Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose
Fierce Pharma
Eli Lilly
Incyte
olumiant
safety data
Humira
rheumatoid arthritis
Flag link:
4 Blockbuster Drug Launches to Watch in 2019
4 Blockbuster Drug Launches to Watch in 2019
Motley Fool
drug launches
AbbVie
Alexion Pharmaceuticals
Aimmune Therapeutics
Skyrizi
psoriasis
Upadacitinib
rheumatoid arthritis
Ultomiris
PNH
AR101
peanut allergy
Flag link:
EMA sounds its own safety alarm for Pfizer blockbuster, but they’re also not forcing a limit on dosing — yet
EMA sounds its own safety alarm for Pfizer blockbuster, but they’re also not forcing a limit on dosing — yet
Endpoints
Pfizer
Xeljanz
Europe
EMA
rheumatoid arthritis
Flag link:
2 Biotech Stocks With Major Incoming Catalysts
2 Biotech Stocks With Major Incoming Catalysts
Yahoo/Motley Fool
Axsome Therapeutics
AXS-05
depression
Galapagos
filgotinib
Gilead Sciences
rheumatoid arthritis
Flag link:
Pfizer drops higher dose treatment arm in Xeljanz post-marketing study due to safety issues
Pfizer drops higher dose treatment arm in Xeljanz post-marketing study due to safety issues
CP Wire
Pfizer
Xeljanz
post-marketing studies
FDA
rheumatoid arthritis
ulcerative colitis
Flag link:
Pfizer drops higher dose treatment arm in Xeljanz post-marketing study due to safety issues
Pfizer
Xeljanz
post-marketing studies
FDA
rheumatoid arthritis
ulcerative colitis
Flag link:
AbbVie’s JAK inhibitor upadacitinib gets Priority Review
AbbVie’s JAK inhibitor upadacitinib gets Priority Review
Pharmaforum
AbbVie
upadacatinib
FDA
priority review
rheumatoid arthritis
Humira
Flag link:
Could Gilead and Galapagos' JAK inhibitor lead the class? Wall Street thinks it has a chance.
Could Gilead and Galapagos' JAK inhibitor lead the class? Wall Street thinks it has a chance.
Biopharma Dive
Gilead Sciences
Galapagos
JAK inhibitors
rheumatoid arthritis
filgotinib
Flag link:
Generic arthritis drug comes up short against inflammation in heart disease
Generic arthritis drug comes up short against inflammation in heart disease
Stat
generics
rheumatoid arthritis
methotrexate
Flag link:
Johnson & Johnson drops OSE’s rheumatoid arthritis drug
Johnson & Johnson drops OSE’s rheumatoid arthritis drug
Fierce Biotech
JNJ
OSE Immuotherapeutics
FR104
autoimmune disease
rheumatoid arthritis
Flag link:
AbbVie rheumatoid arthritis drug succeeds in late stage trial
AbbVie rheumatoid arthritis drug succeeds in late stage trial
Yahoo/Reuters
AbbVie
clinical trials
rheumatoid arthritis
Upadacitinib
Flag link:
GlaxoSmithKline’s rheumatoid arthritis prospect misses phase 2 endpoint
GlaxoSmithKline’s rheumatoid arthritis prospect misses phase 2 endpoint
Fierce Pharma
GSK
rheumatoid arthritis
GSK3196165
clinical trials
Flag link:
A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis
A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis
Yahoo/Motley Fool
AbbVie
Gilead Sciences
FDA
rheumatoid arthritis
Upadacitinib
filgotinib
Flag link:
Galapagos shares surge on RA drug trial results
Galapagos shares surge on RA drug trial results
Pharmaforum
Gilead Sciences
Galapagos
filgotinib
rheumatoid arthritis
clinical tgrials
Flag link:
Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key
Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key
Fierce Biotech
Gilead Sciences
JAK inhibitors
filgotinib
rheumatoid arthritis
Flag link:
Amgen Announces Top-Line Data From Remicade Biosimilar Study
Amgen Announces Top-Line Data From Remicade Biosimilar Study
Yahoo/Zacks.com
Amgen
ABP 710
JNJ
Merck
Remicade
biosimilars
rheumatoid arthritis
Flag link:
3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate
3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate
Yahoo/Motley Fool
AbbVie
Huimra
Upadacitinib
rheumatoid arthritis
Flag link:
AbbVie to submit upadacitinib to FDA after 5th trial win
AbbVie to submit upadacitinib to FDA after 5th trial win
Fierce Pharma
AbbVie
Upadacitinib
rheumatoid arthritis
FDA
JAK inhibitors
Flag link:

Pages